Abstract
A new series of novel 1-(4-oxo-3-(3-methoxyphenyl)-3H-quinazolin-2-yl)-4-(substituted) thiosemicarbazides were synthesized by the reaction of 2-hydrazino-3-(3-methoxyphenyl) quinazolin-4(3H)-one with various methyl esters of dithiocarbamic acid. When tested for their in vitro antitubercular activity using H37Rv strain on Middle brook 7H11 agar slants with OADC growth supplement, all the test compounds inhibited the growth of Mycobacterium tuberculosis at microgram concentration. Among the test compounds, three compounds 1-(4-oxo-3-(3-methoxy phenyl)-3H-quinazolin-2-yl)-4-(thiazol- 2-yl) thiosemicarbazide (A1), 1-(4-oxo-3-(3-methoxyphenyl)-3H-quinazolin-2-yl)-4-(4-chlorophenyl) thiosemi-carbazide (A6) and 1-(4-oxo-3-(3-methoxyphenyl)-3H-quinazolin-2-yl)-4-(4-nitrophenyl) thiosemicarbazide (A7) were inhibited at the 6 μg/mL concentration. The title compounds are also screened for the antimicrobial activity against some other gram positive and gram negative bacteria by agar dilution method, compounds A6 and A7 were emerged as the most active compounds of the series. Compound A6 showed most potent activity against E. coli, K. pneumoniae and B. subtilis.
Keywords: Antitubercular, quinazolinone, thiosemicarbazide, anti-bacterial
Anti-Infective Agents
Title:Synthesis and Antibacterial Activity of Some Novel 1-(4-Oxo-3-(3- methoxyphenyl)-3H-quinazolin-2-yl)-4-(substituted) thiosemicarbazides
Volume: 10 Issue: 2
Author(s): V. Alagarsamy, B. Arun kumar, P. Parthiban, R. V. Sheorey and V. Raja Solomon
Affiliation:
Keywords: Antitubercular, quinazolinone, thiosemicarbazide, anti-bacterial
Abstract: A new series of novel 1-(4-oxo-3-(3-methoxyphenyl)-3H-quinazolin-2-yl)-4-(substituted) thiosemicarbazides were synthesized by the reaction of 2-hydrazino-3-(3-methoxyphenyl) quinazolin-4(3H)-one with various methyl esters of dithiocarbamic acid. When tested for their in vitro antitubercular activity using H37Rv strain on Middle brook 7H11 agar slants with OADC growth supplement, all the test compounds inhibited the growth of Mycobacterium tuberculosis at microgram concentration. Among the test compounds, three compounds 1-(4-oxo-3-(3-methoxy phenyl)-3H-quinazolin-2-yl)-4-(thiazol- 2-yl) thiosemicarbazide (A1), 1-(4-oxo-3-(3-methoxyphenyl)-3H-quinazolin-2-yl)-4-(4-chlorophenyl) thiosemi-carbazide (A6) and 1-(4-oxo-3-(3-methoxyphenyl)-3H-quinazolin-2-yl)-4-(4-nitrophenyl) thiosemicarbazide (A7) were inhibited at the 6 μg/mL concentration. The title compounds are also screened for the antimicrobial activity against some other gram positive and gram negative bacteria by agar dilution method, compounds A6 and A7 were emerged as the most active compounds of the series. Compound A6 showed most potent activity against E. coli, K. pneumoniae and B. subtilis.
Export Options
About this article
Cite this article as:
Alagarsamy V., Arun kumar B., Parthiban P., V. Sheorey R. and Raja Solomon V., Synthesis and Antibacterial Activity of Some Novel 1-(4-Oxo-3-(3- methoxyphenyl)-3H-quinazolin-2-yl)-4-(substituted) thiosemicarbazides, Anti-Infective Agents 2012; 10 (2) . https://dx.doi.org/10.2174/2211362611208020105
DOI https://dx.doi.org/10.2174/2211362611208020105 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of Major Drug Metabolizing CYPs by Common Herbal Medicines used by HIV/AIDS Patients in Africa– Implications for Herb- Drug Interactions
Drug Metabolism Letters Recent Advances in the Development of Anti-Infective Prophylactic and/or Therapeutic Agents Based on Toll-Like Receptor (TLRs)
Recent Patents on Anti-Infective Drug Discovery Graphical Abstracts:
Letters in Drug Design & Discovery Insights into Novel Coronavirus Disease 2019 (COVID-19): Current Understanding, Research, and Therapeutic Updates
Recent Patents on Biotechnology Synthesis and SAR of Some New 4 Substituted 3H-1,2,3,5-oxathiadiazole 2-Oxides as Antifungal Agents
Letters in Drug Design & Discovery Evasion of Host Immunity by Virulent Salmonella: Implications for Vaccine Design
Current Medicinal Chemistry Current Approaches and Future Prospects of Nanomedicine in Tuberculosis Therapy
Recent Patents on Anti-Infective Drug Discovery Monocytes and Macrophages as Cellular Targets in Liver Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Inter-Species/Host-Parasite Protein Interaction Predictions Reviewed
Current Bioinformatics Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Nanobiotechnology: An Efficient Approach to Drug Delivery of Unstable Biomolecules
Current Protein & Peptide Science Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry Enhanced Oral Absorption of All-trans Retinoic Acid upon Encapsulation in Solid Lipid Nanoparticles
Pharmaceutical Nanotechnology The Role of Mineral Deficiencies in Insulin Resistance and Obesity
Current Diabetes Reviews Impairment of T Cell Immunity by the Respiratory Syncytial Virus: Targeting Virulence Mechanisms for Therapy and Prophylaxis
Current Medicinal Chemistry 1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story So Far And Perspectives (Part 2): Action in Other Targets and Antitargets
Current Medicinal Chemistry Graphical Abstracts:
Current Organic Chemistry Artificial Neural Network Analysis of Pharmacokinetic and Toxicity Properties of Lead Molecules for Dengue Fever, Tuberculosis and Malaria
Current Computer-Aided Drug Design Molecular Insight and Binding Pattern Analysis of Shikonin as a Potential VEGFR-2 Inhibitor
Current Enzyme Inhibition Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery